No single ticker was named. Weight-loss & pharma ETFs are one way for retail investors to get exposure. Not a recommendation.
GLP-1s show neuroprotective potential in eye disease
GLP-1 receptor agonists are emerging as a promising therapeutic class for neuroprotection in eye conditions like glaucoma by targeting the gut-brain-immune axis.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.